Literature DB >> 33742125

NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.

Da Song1, Jingqin Lan1,2, Yaqi Chen1, Anyi Liu1, Qi Wu1, Chongchong Zhao3, Yongdong Feng1, Jing Wang4, Xuelai Luo1, Zhixin Cao1, Xiaonian Cao1,5, Junbo Hu6, Guihua Wang7.   

Abstract

Tumor angiogenesis plays vital roles in tumorigenesis and development; regulatory mechanism of angiogenesis is still not been fully elucidated. NSD2, a histone methyltransferase catalyzing di-methylation of histone H3 at lysine 36, has been proved a critical molecule in proliferation, metastasis, and tumorigenesis. But its role in tumor angiogenesis remains unknown. Here we demonstrated that NSD2 promoted tumor angiogenesis in vitro and in vivo. Furthermore, we confirmed that the angiogenic function of NSD2 was mediated by STAT3. Momentously, we found that NSD2 promoted the methylation and activation of STAT3. In addition, mass spectrometry and site-directed mutagenesis assays revealed that NSD2 methylated STAT3 at lysine 163 (K163). Meanwhile, K to R mutant at K163 of STAT3 attenuated the activation and angiogenic function of STAT3. Taken together, we conclude that methylation of STAT3 catalyzed by NSD2 promotes the activation of STAT3 pathway and enhances the ability of tumor angiogenesis. Our findings investigate a NSD2-dependent methylation-phosphorylation regulation pattern of STAT3 and reveal that NSD2/STAT3/VEGFA axis might be a potential target for tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33742125     DOI: 10.1038/s41388-021-01747-z

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  44 in total

Review 1.  Molecular regulation of angiogenesis and lymphangiogenesis.

Authors:  Ralf H Adams; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2007-06       Impact factor: 94.444

Review 2.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

3.  Bevacizumab in colorectal cancer: it should have worked.

Authors:  Leonard B Saltz
Journal:  Lancet Oncol       Date:  2016-09-19       Impact factor: 41.316

4.  VEGF and FGF prime vascular tube morphogenesis and sprouting directed by hematopoietic stem cell cytokines.

Authors:  Amber N Stratman; Michael J Davis; George E Davis
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

5.  Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization.

Authors:  Amber N Stratman; Amy E Schwindt; Kristine M Malotte; George E Davis
Journal:  Blood       Date:  2010-08-25       Impact factor: 22.113

Review 6.  Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer.

Authors:  Miriam Canavese; Doan T M Ngo; Guy J Maddern; Jennifer E Hardingham; Timothy J Price; Ehud Hauben
Journal:  Int J Cancer       Date:  2017-02-02       Impact factor: 7.396

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Authors:  Dominiek Smeets; Ian S Miller; Darran P O'Connor; Sudipto Das; Bruce Moran; Bram Boeckx; Timo Gaiser; Johannes Betge; Ana Barat; Rut Klinger; Nicole C T van Grieken; Chiara Cremolini; Hans Prenen; Massimiliano Mazzone; Jeroen Depreeuw; Orna Bacon; Bozena Fender; Joseph Brady; Bryan T Hennessy; Deborah A McNamara; Elaine Kay; Henk M Verheul; Neerincx Maarten; William M Gallagher; Verena Murphy; Jochen H M Prehn; Miriam Koopman; Cornelis J A Punt; Fotios Loupakis; Matthias P A Ebert; Bauke Ylstra; Diether Lambrechts; Annette T Byrne
Journal:  Nat Commun       Date:  2018-10-05       Impact factor: 14.919

Review 10.  Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.

Authors:  Yolla Haibe; Malek Kreidieh; Hiba El Hajj; Ibrahim Khalifeh; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Front Oncol       Date:  2020-02-27       Impact factor: 6.244

View more
  3 in total

Review 1.  The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.

Authors:  Iuliia Topchu; Rajendra P Pangeni; Igor Bychkov; Sven A Miller; Evgeny Izumchenko; Jindan Yu; Erica Golemis; John Karanicolas; Yanis Boumber
Journal:  Cell Mol Life Sci       Date:  2022-05-09       Impact factor: 9.207

Review 2.  Structural and functional specificity of H3K36 methylation.

Authors:  Ulysses Tsz Fung Lam; Bryan Kok Yan Tan; John Jia Xin Poh; Ee Sin Chen
Journal:  Epigenetics Chromatin       Date:  2022-05-18       Impact factor: 5.465

3.  Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.

Authors:  Shasha Wang; Ning Lou; Rongrong Luo; Xuezhi Hao; Yutao Liu; Lin Wang; Yuankai Shi; Xiaohong Han
Journal:  J Transl Med       Date:  2022-05-31       Impact factor: 8.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.